TRYNGOLZA
olezarsen- Familial Chylomicronemia Syndrome
- Severe Hypertriglyceridemia
Most recent annual filing: 2026-02-26
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Mesyl phosphoramidate backbone chemistry designed to improve therapeutic index and durability by increasing metabolic stability, improving potency and reducing non-specific protein interactions; multiple new programs in preclinical development
Bicyclic peptide technology licensing collaboration with Bicycle Therapeutics to expand LICA platform for delivery of oligonucleotides to skeletal and cardiac muscle and potentially across the blood-brain barrier via transferrin receptor 1 binding
Targets: transferrin receptor 1
Camelid-derived antibody platform licensed exclusively for systemic delivery of RNA-targeted therapeutics across the blood-brain barrier to CNS targets; first program advanced to preclinical development in 2025
Collaboration leveraging RNA-targeted therapeutics expertise combined with Metagenomi next-generation CRISPR-Cas gene editing systems to discover and develop drugs for validated and novel genetic targets; up to eight targets total
Systemic delivery platform for RNA-targeted therapeutics using camelid-derived single-domain antibodies to cross the blood-brain barrier and address CNS targets; focus area: central nervous system diseases
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.